268 related articles for article (PubMed ID: 10809901)
1. A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility.
Fritsche A; Stefan N; Hardt E; Schützenauer S; Häring H; Stumvoll M
Eur J Clin Invest; 2000 May; 30(5):411-8. PubMed ID: 10809901
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
4. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
Greenbaum CJ; Prigeon RL; D'Alessio DA
Diabetes; 2002 Apr; 51(4):951-7. PubMed ID: 11916912
[TBL] [Abstract][Full Text] [Related]
5. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion.
Fritsche A; Stefan N; Hardt E; Häring H; Stumvoll M
Diabetologia; 2000 Jul; 43(7):852-8. PubMed ID: 10952457
[TBL] [Abstract][Full Text] [Related]
7. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
[TBL] [Abstract][Full Text] [Related]
8. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans.
Ahrén B; Holst JJ; Mari A
Diabetes Care; 2003 Oct; 26(10):2860-4. PubMed ID: 14514592
[TBL] [Abstract][Full Text] [Related]
9. Comparison of an oral mixed meal plus arginine and intravenous glucose, GLP-1 plus arginine to unmask residual islet function in longstanding type 1 diabetes.
Uitbeijerse BS; Nijhoff MF; de Koning EJP
Am J Physiol Endocrinol Metab; 2024 May; 326(5):E673-E680. PubMed ID: 38446636
[TBL] [Abstract][Full Text] [Related]
10. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
Kjems LL; Holst JJ; Vølund A; Madsbad S
Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
[TBL] [Abstract][Full Text] [Related]
11. Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction.
Stumvoll M; Fritsche A; Stefan N; Hardt E; Häring H
J Clin Endocrinol Metab; 2001 Mar; 86(3):1235-9. PubMed ID: 11238514
[TBL] [Abstract][Full Text] [Related]
12. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
13. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
14. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.
Ahrén B; Larsson H; Holst JJ
J Clin Endocrinol Metab; 1997 Feb; 82(2):473-8. PubMed ID: 9024239
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
Egan JM; Meneilly GS; Habener JF; Elahi D
J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
[TBL] [Abstract][Full Text] [Related]
17. Effect of acute hyperglycemia on insulin secretion in humans.
Toschi E; Camastra S; Sironi AM; Masoni A; Gastaldelli A; Mari A; Ferrannini E; Natali A
Diabetes; 2002 Feb; 51 Suppl 1():S130-3. PubMed ID: 11815471
[TBL] [Abstract][Full Text] [Related]
18. Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients.
Kruszynska YT; Goulas S; Wollen N; McIntyre N
J Hepatol; 1998 Feb; 28(2):280-91. PubMed ID: 9514541
[TBL] [Abstract][Full Text] [Related]
19. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
20. Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity.
Solomon TP; Knudsen SH; Karstoft K; Winding K; Holst JJ; Pedersen BK
J Clin Endocrinol Metab; 2012 Dec; 97(12):4682-91. PubMed ID: 23043193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
